Home Dr. Reddy Is Transitioning From A Pure Generic Player To An Innovator
 

Keywords :   


Dr. Reddy Is Transitioning From A Pure Generic Player To An Innovator

2016-02-18 00:09:33| Biotech - Topix.net

Currently it is just the warning letter that is at the top of everybody's mind when it comes to investing in Dr. Reddy. By 2022, Proprietary product business alone should contribute about INR 70 per share to the EPS.

Tags: to player pure generic

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.04John Lewis job applicants get questions beforehand
26.04Wanhua Chemical Launches Barcelona R&D Center
26.04Phase Change Cosmetic Patented by Amorepacific
26.04Farm Progress America, April 26, 2024
26.04Farm Progress America, April 26, 2024
26.04TikTok China parent firm says no plans to sell app
26.04Why green steam is a hot issue for business
26.04The ex-flight attendant who now leads the airline
More »